Comparing a risankizumab biosimilar to Skyrizi in healthy adults
Part of Skin clinical trials.
This study tests a new biosimilar medicine (CKD-704) to see how it compares to the approved Skyrizi treatments for healthy adults. It checks how the medicine moves through the body, its safety, and how the immune system responds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a healthy adult between 18 and 55 years old.
- You do not smoke more than 10 cigarettes per week.
- You are willing to avoid alcohol for 48 hours before the medicine is given and limit drinking overall.
- You have not taken any anti-IL-12/23 or anti-IL-23 medicines before.
- You do not have any active infections, history of tuberculosis, or major health problems.
- You agree to use effective birth control and not donate sperm for a while.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at what’s happening inside the body in people with plaque psoriasis who start certain biologic medicines that target the IL-23/IL-17 immune pathway. It may help explain why these treatments work and what body changes are linked to response.
This study compares a new biosimilar drug (SB35) to the approved drug Taltz in healthy volunteers. The purpose is to check how the body processes both drugs and if they are similar. Participation involves receiving injections and multiple health checks over several months.
This trial studies how the drug risankizumab moves through your body after being given through a vein or under the skin. It helps doctors understand the best way to give the medicine to patients.
This study tests how well a medicine called Risankizumab works for people with psoriatic arthritis. It is for adults who have had symptoms for at least 6 months and have not had enough help from at least one other arthritis medicine.
This study looks at how risankizumab (Skyrizi) affects the quality of life for adults with moderate-to-severe plaque psoriasis. It is an observational study, meaning no new treatments are given—researchers simply follow patients who are already being treated with risankizumab as part of their regular care.
This trial tests a new drug called GSK5926371 for people with certain autoimmune diseases that affect the joints, skin, and other tissues. It aims to see if the drug is safe and how well it works.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.